These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 14616817

  • 1. Extensive condyloma acuminata treated with imiquimod 5% cream: a case report.
    Cox JT.
    Clin Exp Dermatol; 2003 Nov; 28 Suppl 1():51-4. PubMed ID: 14616817
    [Abstract] [Full Text] [Related]

  • 2. Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: an open-label, noncomparative study.
    Saiag P, Bauhofer A, Bouscarat F, Aquilina C, Ortonne JP, Dupin N, Mougin C.
    Br J Dermatol; 2009 Oct; 161(4):904-9. PubMed ID: 19466962
    [Abstract] [Full Text] [Related]

  • 3. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.
    Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL, Hougham AJ, Schmitt KA.
    Arch Dermatol; 1998 Jan; 134(1):25-30. PubMed ID: 9449906
    [Abstract] [Full Text] [Related]

  • 4. Topical imiquimod 5% cream in external anogenital warts: a randomized, double-blind, placebo-controlled study.
    Arican O, Guneri F, Bilgic K, Karaoglu A.
    J Dermatol; 2004 Aug; 31(8):627-31. PubMed ID: 15492435
    [Abstract] [Full Text] [Related]

  • 5. Topical imiquimod: a review of its use in genital warts.
    Perry CM, Lamb HM.
    Drugs; 1999 Aug; 58(2):375-90. PubMed ID: 10473026
    [Abstract] [Full Text] [Related]

  • 6. Sinecatechins and imiquimod as proactive sequential therapy of external genital and perianal warts in adults.
    Schöfer H, Tatti S, Lynde CW, Skerlev M, Hercogová J, Rotaru M, Ballesteros J, Calzavara-Pinton P.
    Int J STD AIDS; 2017 Dec; 28(14):1433-1443. PubMed ID: 28566057
    [Abstract] [Full Text] [Related]

  • 7. Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT.
    Gilson R, Nugent D, Bennett K, Doré CJ, Murray ML, Meadows J, Haddow LJ, Lacey C, Sandmann F, Jit M, Soldan K, Tetlow M, Caverly E, Nathan M, Copas AJ.
    Health Technol Assess; 2020 Sep; 24(47):1-86. PubMed ID: 32975189
    [Abstract] [Full Text] [Related]

  • 8. Topical imiquimod 5% cream as an effective treatment for external genital and perianal warts in different patient populations.
    Sauder DN, Skinner RB, Fox TL, Owens ML.
    Sex Transm Dis; 2003 Feb; 30(2):124-8. PubMed ID: 12567169
    [Abstract] [Full Text] [Related]

  • 9. [Mechanisms of imiquimod indirect antiviral activity].
    Hober D, Ajram L, Chehadeh W, Lazrek M, Goffard A, Dewilde A, Wattré P.
    Ann Biol Clin (Paris); 2005 Feb; 63(2):155-63. PubMed ID: 15771973
    [Abstract] [Full Text] [Related]

  • 10. Human papillomavirus (HPV) viral load and HPV type in the clinical outcome of HIV-positive patients treated with imiquimod for anogenital warts and anal intraepithelial neoplasia.
    Sanclemente G, Herrera S, Tyring SK, Rady PL, Zuleta JJ, Correa LA, He Q, Wolff JC.
    J Eur Acad Dermatol Venereol; 2007 Sep; 21(8):1054-60. PubMed ID: 17714124
    [Abstract] [Full Text] [Related]

  • 11. Increased frequency of dosing of imiquimod 5% cream in the treatment of external genital warts in women.
    Trofatter KF, Ferenczy A, Fife KH.
    Int J Gynaecol Obstet; 2002 Feb; 76(2):191-3. PubMed ID: 11818121
    [No Abstract] [Full Text] [Related]

  • 12. [A model-based comparison of cost effectiveness of imiquimod versus podophyllotoxin for the treatment of external anogenital warts in France].
    Lafuma A, Monsonego J, Moyal-Barracco M, Pribil C.
    Ann Dermatol Venereol; 2003 Feb; 130(8-9 Pt 1):731-6. PubMed ID: 14576602
    [Abstract] [Full Text] [Related]

  • 13. [Efficacy and safety of 5% imiquimod cream in external genital warts: a 6 month follow-up evaluation].
    Vexiau D, Decuypère L, Moyse D, Aractingi S.
    Ann Dermatol Venereol; 2005 Nov; 132(11 Pt 1):845-51. PubMed ID: 16327713
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of imiquimod for the therapy of external genital and anal warts in comparison with destructive therapies.
    Schöfer H.
    Br J Dermatol; 2007 Dec; 157 Suppl 2():52-5. PubMed ID: 18067633
    [Abstract] [Full Text] [Related]

  • 15. Treatment of human papillomavirus in childhood with imiquimod 5% cream.
    Brandt HR, Fernandes JD, Patriota RC, Criado PR, Belda Junior W.
    An Bras Dermatol; 2010 Dec; 85(4):549-53. PubMed ID: 20944919
    [Abstract] [Full Text] [Related]

  • 16. Effect of adjuvant imiquimod 5% cream on sustained clearance of anogenital warts following laser treatment.
    Hoyme UB, Hagedorn M, Schindler AE, Schneede P, Hopfenmüller W, Schorn K, Eul A.
    Infect Dis Obstet Gynecol; 2002 Dec; 10(2):79-88. PubMed ID: 12530484
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of anogenital warts in children with topical 0.05% podofilox gel and 5% imiquimod cream.
    Moresi JM, Herbert CR, Cohen BA.
    Pediatr Dermatol; 2001 Dec; 18(5):448-50; discussion 452. PubMed ID: 11737696
    [Abstract] [Full Text] [Related]

  • 19. Treatment of genital warts with an immune-response modifier (imiquimod).
    Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas JM.
    J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):230-9. PubMed ID: 9486679
    [Abstract] [Full Text] [Related]

  • 20. Management of female genital warts with an analog of imiquimod 2% in cream: a randomized, double-blind, placebo-controlled study.
    Syed TA, Ahmadpour OA, Ahmad SA, Ahmad SH.
    J Dermatol; 1998 Jul; 25(7):429-33. PubMed ID: 9714974
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.